Market research
TGKQ.F Precipio, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 367K
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- 0.0%
- Beta
- 2.04
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US74019L5030
- Market cap
- 367K
- P/E ratio
- Not available
- Analyst target
- 7
- Dividend yield
- 0.0%
- Beta
- 2.04
About
About Precipio, Inc
Precipio, Inc., a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; HemeScreen, a suite of robust genetic diagnostic panels; and COVID-19 antibody tests. It sells ICE- technology kits to bio-pharma customers. The company is based in New Haven, Connecticut.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the TGKQ.F discussion.
5 years, 5 months ago
Precipio, Inc is currently in a long term uptrend where the price is trading 14.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.3.
Precipio, Inc's total revenue rose by 182.1% to $2M since the same quarter in the previous year.
Its net income has increased by 50.6% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.0% to $-1M since the same quarter in the previous year.
Based on the above factors, Precipio, Inc gets an overall score of 5/5.